Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yali Zhong

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Oncotarget|November 4, 2015
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitroDandan Yu, Yali Zhong, Xiaoran Li, et al.
Anticancer Research|January 2, 2016
Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell CarcinomaYasai Ji, Xiaoli Li, Yaqing Li, et al.
ACS Biomaterials Science & Engineering|May 13, 2024
H<sub>2</sub>S-Powered Nanomotors for Active Therapy of Tumors by Inducing Ferroptosis and Lactate-Pyruvate Axis DisordersWeixin Wang, Renquan Fu, Rui Gao, et al.
Signal Transduction and Targeted Therapy|March 10, 2026
Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysisXuan Zhao, Jinyan Liu, Zhen Zhang, et al.
Oncotarget|August 25, 2016
Generation of TALEN-mediated FH knockout rat modelDandan Yu, Yali Zhong, Xiaoran Li, et al.
RSC Advances|May 11, 2022
Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat dietZhirui Fan, Lifeng Li, Xiaoli Li, et al.
Oncotarget|January 12, 2017
Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancersYali Zhong, Xiaoli Li, Yasai Ji, et al.
International Journal of Cancer|November 29, 2022
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trialShuiling Jin, Ruihua Zhao, Chuang Zhou, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Oncotarget|November 4, 2015
ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitroDandan Yu, Yali Zhong, Xiaoran Li, et al.
Anticancer Research|January 2, 2016
Aldehyde Dehydrogenase-1 Expression Predicts Unfavorable Outcomes in Patients with Esophageal Squamous Cell CarcinomaYasai Ji, Xiaoli Li, Yaqing Li, et al.
ACS Biomaterials Science & Engineering|May 13, 2024
H<sub>2</sub>S-Powered Nanomotors for Active Therapy of Tumors by Inducing Ferroptosis and Lactate-Pyruvate Axis DisordersWeixin Wang, Renquan Fu, Rui Gao, et al.
Signal Transduction and Targeted Therapy|March 10, 2026
Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysisXuan Zhao, Jinyan Liu, Zhen Zhang, et al.
Oncotarget|August 25, 2016
Generation of TALEN-mediated FH knockout rat modelDandan Yu, Yali Zhong, Xiaoran Li, et al.
RSC Advances|May 11, 2022
Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat dietZhirui Fan, Lifeng Li, Xiaoli Li, et al.
Oncotarget|January 12, 2017
Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancersYali Zhong, Xiaoli Li, Yasai Ji, et al.
International Journal of Cancer|November 29, 2022
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trialShuiling Jin, Ruihua Zhao, Chuang Zhou, et al.
Pageof 3